Incidence of ≥Gr3 NC AEs in patients based on pre-CAR factors. (A) Dot plot of ≥Gr3 NC AEs in patients based on the presence of EM (extramedullary) disease. (B) Dot plot of ≥Gr3 NC AEs in patients based on the presence of CNS disease. (C) Dot plot of ≥Gr3 NC AEs in patients based on the age. (D) Dot plot of ≥Gr3 NC AEs in patients based on the sex. (E) Dot plot of ≥Gr3 NC AEs in patients based on the ethnicity. (F) Dot plot of ≥Gr3 NC AEs in patients based on the race; because of small numbers, analysis was grouped into White vs non-White, with non-White including African American, Asian, Hawaiian/Pacific Islander, and multirace; 15 patients with unknown race were excluded from this analysis. (G) Dot plot of ≥Gr3 NC AEs in patients based on the number of prior treatment regimens, excluding prior hematopoietic stem cell transplantation (HSCT). (H) Dot plot of ≥Gr3 NC AEs in patients based on prior HSCTs. (I) Dot plot of ≥Gr3 NC AEs in patients based on prior CAR T-cell therapy. (J) Dot plot of ≥Gr3 NC AEs in patients based on the prior receipt of blinatumomab. (K) Dot plot of ≥Gr3 NC AEs in patients based on the prior receipt of inotuzumab. CNS1, 0 blasts on cytospin; CNS2+, some degree of CNS disease, either CNS2 (<5/μL white blood cells, cytospin positive for blasts) or CNS3 (≥ 5/μL white blood cells, cytospin positive for blasts).